Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × ALK+ Advanced NSCLC × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 593 Neoplasms 533 Prostatic Neoplasms 268 Carcinoma, Non-Small-Cell Lung 252 Colorectal Neoplasms 239 Lung Neoplasms 202 Melanoma 150 Multiple Myeloma 146 Neoplasm Metastasis 142 Pancreatic Neoplasms 136 Ovarian Neoplasms 125 Head and Neck Neoplasms 119 Leukemia, Myeloid, Acute 114 Colonic Neoplasms 111 Carcinoma, Hepatocellular 107 Brain Neoplasms 106 Squamous Cell Carcinoma of Head and Neck 103 Stomach Neoplasms 95 Uterine Cervical Neoplasms 94 Recurrence 94 Lymphoma 91 Glioblastoma 77 Urinary Bladder Neoplasms 75 Hematologic Neoplasms 73 Lymphoma, Follicular 72 Precursor Cell Lymphoblastic Leukemia-Lymphoma 69 Lymphoma, Non-Hodgkin 67 Motor Activity 65 Carcinoma, Renal Cell 64 Glioma 63

Interventions

brigatinib 1 alectinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03596866 2025-09-12

ALTA-3

Takeda

Phase 3 Completed

248 enrolled 20 charts

ALK+ Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡